mortality/aging
• approximately 20% die in late gestation-postnatally
|
cardiovascular system
N |
• in the heart, no morphological defects are seen in the structure of coronary vessels and cardiac microcirculation, or in atrioventricular valves and the ventricular outflow tract and mutants have normal numbers of cardiomyocytes
|
• mutants that die exhibit vascular abnormalities in the lung
|
respiratory system
• mutants that die exhibit vascular abnormalities in the lung
|
• mutants treated with urethane exhibit chronic lung inflammation unlike control lungs
|
• mutants exhibit increased numbers of lung adenomas and larger tumor diameters 30 weeks after initial urethane injection compared to controls
|
neoplasm
• mutants exhibit increased numbers of lung tumors (adenomas) and larger tumor diameters 30 weeks after initial urethane injection compared to controls
• mutants exhibit increased lung tumorigenesis after MCA/BHT treatment
• tumors from mutants treated with urethane exhibit increased proliferation compared to tumors from controls
|
• mutants exhibit increased numbers of lung adenomas and larger tumor diameters 30 weeks after initial urethane injection compared to controls
|
immune system
• mutants treated with urethane exhibit chronic lung inflammation unlike control lungs
|
homeostasis/metabolism
• mutants exhibit increased numbers of lung tumors (adenomas) and larger tumor diameters 30 weeks after initial urethane injection compared to controls
• mutants exhibit increased lung tumorigenesis after MCA/BHT treatment
• tumors from mutants treated with urethane exhibit increased proliferation compared to tumors from controls
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
lung cancer | DOID:1324 |
OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210 |
J:167773 |